Title |
Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients
|
---|---|
Published in |
Biotechnology Reports, May 2017
|
DOI | 10.1016/j.btre.2017.05.002 |
Pubmed ID | |
Authors |
Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Zack Scott, Jenna Elder, Stephen T. Sonis, Richard Straube, Oreola Donini |
Abstract |
Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 36 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 14% |
Student > Bachelor | 4 | 11% |
Other | 3 | 8% |
Student > Ph. D. Student | 3 | 8% |
Professor | 2 | 6% |
Other | 4 | 11% |
Unknown | 15 | 42% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 31% |
Biochemistry, Genetics and Molecular Biology | 5 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Computer Science | 1 | 3% |
Agricultural and Biological Sciences | 1 | 3% |
Other | 2 | 6% |
Unknown | 15 | 42% |